Otologicals

VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone

Retrieved on: 
Monday, August 2, 2021

AMZEEQ and ZILXI were approved for the pilot zone among other innovative dermatology products, said Lele Zhang, CEO of Cutia Therapeutics.

Key Points: 
  • AMZEEQ and ZILXI were approved for the pilot zone among other innovative dermatology products, said Lele Zhang, CEO of Cutia Therapeutics.
  • ZILXI or AMZEEQ should not be used in people who are allergic to ZILXI, AMZEEQ, or any tetracycline medicine.
  • ZILXI and AMZEEQ are flammable and fire, flame, and smoking must be avoided when applying and right after applying ZILXI or AMZEEQ.
  • For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.

Study: Common Drugs Associated with Increased Risk for Cardiac Arrhythmia and Sudden Death in Elderly Patients

Retrieved on: 
Wednesday, July 28, 2021

This means outcome studies including the measure of sudden death based on large clinical data sets are especially important to assess the risk of drug-induced arrhythmia.

Key Points: 
  • This means outcome studies including the measure of sudden death based on large clinical data sets are especially important to assess the risk of drug-induced arrhythmia.
  • Of the short-term drugs, researchers found the antibiotics levofloxacin increased the risk of cardiac arrhythmia or sudden death by 51% compared to the amoxicillin control, while erythromycin had an increased risk of 63%.
  • The anti-nausea drug ondansetron increased the risk of a cardiac adverse event by 205%, while the antifungal fluconazole increased the risk by 123%.
  • Current patients prescribed the antipsychotics showed an increased risk of arrhythmia or sudden death of 118% compared to patients who never received the drug.

Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management

Retrieved on: 
Tuesday, July 20, 2021

Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R.

Key Points: 
  • Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R.
  • Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica).
  • Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica.
  • Scilexs SP-102 (SEMDEXA) is currently being evaluated in a pivotal Phase 3 clinical trial in the U.S. in patients with lumbosacral radicular pain (sciatica).

Global Acetic Acid Market to 2027 - Size, Share, Outlook and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021

Among the application, vinyl acetate monomer segment held dominant position in the global Acetic Acid market in 2019 and is also expected to retain its dominance during the forecast period.

Key Points: 
  • Among the application, vinyl acetate monomer segment held dominant position in the global Acetic Acid market in 2019 and is also expected to retain its dominance during the forecast period.
  • This trend is further expected to foster demand for acetic acid during the forecast period.
  • Such trends in Asia Pacific is expected to boost demand for Acetic Acid in this region during the forecast period.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision regarding future products launches, technology upgradation, market expansion, and marketing tactics
    The global acetic acid market report caters to various stakeholders in this industry including investors, suppliers, acetic acid manufacturers, distributors, new entrants, and financial analysts

ALK Acquires OTIPRIO® (ciprofloxacin otic suspension), Broadening Treatment Solutions for Healthcare Providers and Patients

Retrieved on: 
Thursday, June 3, 2021

Additionally, ALK will also now offer our other allergy immunotherapy products and penicillin allergy testing to an expanded set of healthcare provider specialties."

Key Points: 
  • Additionally, ALK will also now offer our other allergy immunotherapy products and penicillin allergy testing to an expanded set of healthcare provider specialties."
  • OTIPRIO is a sterile, preservative-free, otic suspension of 6 percent ciprofloxacin administered as a single-dose by a healthcare professional.
  • For AOE, OTIPRIO is administered as a single 0.2 mL (12 mg) administration to the external ear canal of each affected ear.
  • The tubes are placed for the treatment of persistent or recurrent otitis media (infection and/or inflammation of the middle ear).

Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology

Retrieved on: 
Saturday, May 22, 2021

Sparrow\xe2\x80\x99s novel approach to treatment of CS is based on recognition that the predominant source of intracellular cortisol is HSD-1.

Key Points: 
  • Sparrow\xe2\x80\x99s novel approach to treatment of CS is based on recognition that the predominant source of intracellular cortisol is HSD-1.
  • That\xe2\x80\x99s formed mostly by HSD-1,\xe2\x80\x9d said Dr. David Katz, Chief Scientific Officer of Sparrow.
  • \xe2\x80\x9cSPI-62 can reduce that pool by up to 90% and was associated with favorable clinical changes in patients with diabetes.
  • Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular corticosteroids in key tissues.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210522005003/en/\n'

MerLion Pharmaceuticals Completes Growth Financing Round

Retrieved on: 
Tuesday, May 18, 2021

\xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.

Key Points: 
  • \xe2\x80\x9cXtoro is an FDA-approved product for the treatment of Acute Otitis Externa in children and adults.
  • Its superior, fast acting properties will aid patients considerably in their recovery.\xe2\x80\x9d\nMerLion Pharmaceuticals GmbH is a is a privately held company biopharmaceutical company headquartered in Berlin, Germany.
  • MerLion is supported by a group of leading global investors.
  • For more information, please visit http://www.merlionpharma.com\nPOELLATH, Munich, Dr. Michael Inhester and Adalbert Makos advised MerLion on the investment and capital raise.\nFinafloxacin is a novel fluoroquinolone antibiotic with best-in-class features.

Injectafer® (ferric carboxymaltose injection) Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients with Iron Deficiency Anemia

Retrieved on: 
Thursday, May 6, 2021

For patients weighing 50 kg (110 lb) or more, Injectafer is administered in two doses of 750 mg separated by at least 7 days for a total cumulative dose of 1500 mg of iron per course.

Key Points: 
  • For patients weighing 50 kg (110 lb) or more, Injectafer is administered in two doses of 750 mg separated by at least 7 days for a total cumulative dose of 1500 mg of iron per course.
  • For patients weighing less than 50 kg (110 lb), each dose is administered as 15 mg/kg body weight.
  • These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment.
  • Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.

Pandemic Causes Women to Have Skin Conditions Often Associated With Teenagers Says DermatologistOnCall

Retrieved on: 
Tuesday, April 20, 2021

Pandemic-related stress is a significant factor in these breakouts.\nWhen people become stressed, their bodies produce cortisol.

Key Points: 
  • Pandemic-related stress is a significant factor in these breakouts.\nWhen people become stressed, their bodies produce cortisol.
  • This causes the skin to produce more sebum or oil.
  • That oil creates a number of issues including clogged pores and feeding the bacteria that live on our faces.
  • The easy-to-use, nationally-available service has become an indispensable tool for uniting doctors and patients in the new digital world.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005952/en/\n'

What Happened Inside Our Bodies During 12 Months of Lockdown? Leading Human Performance System Reports Blood-Based Biomarker Impacts

Retrieved on: 
Wednesday, March 17, 2021

InsideTracker , the leading ultra-personalized performance system, looked at pre- and post-lockdown blood biomarker data among thousands of users to provide an objective measure of the stress and lifestyle impacts of the past year.

Key Points: 
  • InsideTracker , the leading ultra-personalized performance system, looked at pre- and post-lockdown blood biomarker data among thousands of users to provide an objective measure of the stress and lifestyle impacts of the past year.
  • The Word of the Year: Cortisol: Cortisol is the classic stress hormone that impacts immunity, metabolism, sleep, inflammation and performance.
  • When cortisol levels trend above optimal, bodies respond by tapping into stored glucose in muscles and releasing it into the bloodstream.
  • InsideTracker's patented algorithm and expert system transforms the body's biomarker data into knowledge, insights, and customized action plans of science-backed nutrition, fitness, and lifestyle recommendations.